Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 18/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 18/20 | 0.53 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29347172 | 0.82 | DDB1 (0.60) | DDB1CRBNIKZF3 | |
| SCHEMBL21996668 | 0.78 | DDB1 (0.58) | DDB1CRBNALDH1A1CHRM2OPRM1 | |
| SCHEMBL29346395 | 0.78 | CRBN (0.85) | DDB1CRBNALDH1A1CHRM2OPRM1 | |
| SCHEMBL26102935 | 0.77 | CRBN (0.54) | DDB1CRBNALDH1A1CHRM2OPRM1 | |
| SCHEMBL26447957 | 0.76 | DDB1 (0.58) | DDB1CRBNALDH1A1CHRM2OPRM1 | |
| SCHEMBL29347177 | 0.75 | DDB1 (0.52) | DDB1CRBNIKZF3 | |
| SCHEMBL23602077 | 0.74 | DDB1 (0.70) | DDB1CRBNALDH1A1CHRM2OPRM1 | |
| SCHEMBL21759953 | 0.74 | DDB1 (0.70) | DDB1CRBNALDH1A1CHRM2OPRM1 | |
| SCHEMBL22525873 | 0.74 | DDB1 (0.70) | DDB1CRBNALDH1A1CHRM2OPRM1 | |
| SCHEMBL25568638 | 0.74 | CRBN (0.70) | DDB1CRBNALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| EP-4650348-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
| WO-2024150815-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | 田辺三菱製薬株式会社 | 2024-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | DDB1 2368/4885CRBN 1/4885MAP1LC3B 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.